<DOC>
	<DOCNO>NCT01411449</DOCNO>
	<brief_summary>This study regulatory post marketing surveillance Japan , local prospective observational study patient receive Primovist contrast enhancement MRI liver . The objective study ass safety , especially relation renal dysfunction , efficacy use Primovist clinical practice . A total 2,000 patient diagnosis detection identify hepatic tumor recruit follow 7 day injection .</brief_summary>
	<brief_title>Primovist Post-marketing Surveillance Japan</brief_title>
	<detailed_description />
	<criteria>Patients receive Primovist liver MRI Patients contraindicate base product label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Primovist</keyword>
	<keyword>MRI agent</keyword>
</DOC>